🚨🚨🚨5-year update of the OPRA Trial 🔥Supports CRT ➡️chemotherapy as the preferred option to best achieve organ preservation for patients with locally advanced rectal cancer ✅ 5-year organ preservation: 54% vs 39% Fantastic update by Jeremy Jones!! #ASCO23 OncoAlert

New & available #OpenAccess | Proton beam #radiotherapy shows improved local control and progression-free survival in randomized trial for patients with hepatocellular carcinoma. acsjournals.onlinelibrary.wiley.com/doi/full/10.10… OncoAlert #HPBCSM

Join us for our next Medical Student Q&A session on Monday, August 28, at 8 p.m. ET. These sessions feature a RadOnc & a RadOnc resident & provide a platform for med students to learn more about the specialty. Sign-up: ow.ly/3kBb50OvKN1

Calling all fourth year medical students applying to rad onc! Please join us on 8/29 at 4 PM PST for a meet and greet. We’re excited to meet you! Sign up at the link bit.ly/uclaROopenhouse David Geffen School of Medicine at UCLA UCLA Health #radonc

IJROBP - The Red Journal GI editorial team lunch #ASTRO2023. Thank you Jeff Olsen for your fantastic leadership and mentorship as section editor. Looking forward to Michael Chuong ‘s leadership. If we see an uptick in adaptive papers, purely coincidence 😁

Key conclusions: 🔵 Rectal cancer is heterogeneous! 🔵 RT ⬇️ pelvic recurrence but may be omitted in select patients with MRI defined- low risk disease 🔵 TNT is preferred for high risk disease 🔵 CRT --> chemo sequence preferred for NOM 🔥🔥🔥 Multi-D collaboration is CRITICAL!

🚨🚨🚨PREOPANC-2 dropped! For AR or BR-PDAC, neoadjuvant FFX and neoadjuvant Gemcitabine based CRT (36 Gy/15 fx) had comparable outcomes. mOS was 21.9 m with FFX arm vs 21.3 m with CRT (HR 0.87; 95% CI 0.68-1.12, p=0.28), and similar resection rates 77% vs. 75%. #ESMO23

🚨🚨🚨SANO-trial!! Been waiting for this one! Patients with esophagus ACA with cCR after CRT randomized to active surveillance vs. esophagectomy ✅Non-inferior OS and improved QoL with AS approach! This is 🔥🔥🔥 Looking forward to manuscript to unpack the details #ESMO23

Shout out to David Sher for leading my favorite section of the Red Journal: Statistics for the People. As far as I’m aware, no other oncology journal has a recurring column devoted solely to trial design/statistics (I could be wrong!) Thank you, David. Each of the pieces

Out now in Journal of Clinical Oncology! Our work on clinical trial endpoints & inclusion criteria in GI oncology trials, and how we can better leverage RCTs to demonstrate the value of RT going forward. With William A Hall, MD and Ted Hong. Brief thread below. ascopubs.org/doi/abs/10.120…

🔥🔥 Long-term outcomes from phase 2 SMART pancreas trial now in press 🔥🔥 ➡️ 136 BRPC/LAPC pts, 50 Gy/5 fx on #MRidian ➡️ Median F/U 22.9 mo from dx, 14.2 mo from SMART ➡️ 2-yr OS 53.6% from dx, 40.5% from SMART ➡️ Grade 3+ late GI toxicity minimal sciencedirect.com/science/articl…

Organ Preservation and Survival by Clinical Response Grade in Patients With Rectal Cancer Treated With Total Neoadjuvant Therapy: A Secondary Analysis of the OPRA Randomized Clinical Trial | Oncology | JAMA Network Open | JAMA Network jamanetwork.com/journals/jaman…

Celebrating National #dressinblue Day at UCLA Health! Loved volunteering with UCLA Gastroenterology and Hepatology & Fola May, MD PhD to spread awareness. This is your reminder to get screened for #ColorectalCancer .

Can’t wait for these incredible, talented, and kind individuals to join our family at UCLA Health!! Ann Raldow, MD, MPH Michael Steinberg MD

Registration open for ASTRO 6/18 webinar on MR-guided SBRT for pancreatic cancer. Free for residents! Sign up here: academy.astro.org/content/2024-e…

🚨🚨ABC-07🚨🚨 Inoperable, locally advanced, cholangiocarcinoma After 4c Gem-Cis, pts randomized to: 2c Gem-Cis (6 total) + RT (50 Gy/5 or 67.5/15) vs. 4c Gem-Cis (8 total) 🟰 DFS 8.6 m vs. 9.0 m ✅ Suggestion of ⬆️ mOS with ☢️ (23.4 vs. 17.2 m) #ASCO24

Learn about MR-guided radiation therapy contouring techniques for pancreatic cancer SBRT from Dr. Ann Raldow, MD, MPH 1 week from today. The live webinar is FREE for ASTRO Members-in-Training with support from the ROI Juan A. del Regato Fund. Register now: bit.ly/GIregistration…

New pod! Tune in to this masterclass in cost, cost effectiveness, and health policy around new technologies. Direct link (may skip): redjournal.org/pb-assets/Heal… Webpage: redjournal.org/audio-do/red-j… (right click to download the audio file)

🚨PRODIGE23🚨 Long term results now published! T3-4 rectal adenocarcinoma Randomized: CRT➡️🔪➡️FOLFOX mFOLFIRINOX ➡️ CRT➡️🔪➡️FOLFOX ✅✅✅Improved OS!!! Looking forward to JANUS clarifying if TNT with FOLFIRINOX vs. FOLFOX improves cCR and/or DFS/OS pubmed.ncbi.nlm.nih.gov/38986769/

Alright friends- I like the "inclusive" algorithm as it acknowledges suitable options with flexibility to balance nuance and most importantly, patient preferences. But... I was asked what I prefer. By request- here is my more limited decision pathway- open to feedback 🙂🤓